Gary K. Lee is Chief Scientific Officer of Lyell Immunopharma, Inc.. Currently has a direct ownership of 8,957 shares of LYEL, which is worth approximately $94,675. The most recent transaction as insider was on Aug 12, 2025, when has been sold 136 shares (Common Stock) at a price of $10.34 per share, resulting in proceeds of $1,406. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 8.96K
94.93% 3M change
83.0% 12M change
Total Value Held $94,675

Gary K. Lee Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 12 2025
SELL
Open market or private sale
$1,406 $10.34 p/Share
136 Reduced 1.5%
8,957 Common Stock
Aug 11 2025
SELL
Open market or private sale
$1,379 $10.53 p/Share
131 Reduced 1.42%
9,093 Common Stock
Feb 10 2025
BUY
Grant, award, or other acquisition
-
112,500 Added 38.9%
176,696 Common Stock
Feb 09 2024
BUY
Grant, award, or other acquisition
-
40,000 Added 43.15%
52,700 Common Stock
GKL

Gary K. Lee

Chief Scientific Officer
South San Francisco, CA

Track Institutional and Insider Activities on LYEL

Follow Lyell Immunopharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LYEL shares.

Notify only if

Insider Trading

Get notified when an Lyell Immunopharma, Inc. insider buys or sells LYEL shares.

Notify only if

News

Receive news related to Lyell Immunopharma, Inc.

Track Activities on LYEL